Brain Tumor Targeted Therapeutic Development Services

Alfa Cytology identifies promising targets in early drug discovery. We develop and implement high-throughput target ID screens that characterize a wide range of analytes from small molecular fragments to biologics. We utilize non-labeled binding technologies such as bio-layer interference (BLI) and surface plasmon resonance (SPR) systems to rapidly establish high-throughput binding screens. Our services can be used to identify binding targets and accurately characterize complex formation rates, complex stability, and affinity.

Alfa Cytology focuses on the role of Tregs in immunosuppression. We can provide drug development services for Tregs targets, mainly through monoclonal antibodies targeting Tregs and small molecule antagonists targeting Tregs. For this important new immune target in brain tumors, we have also developed a relevant drug target cell screening model for the binding capacity and activity of large and small molecule drugs targeting Tregs.

EGFR is often overexpressed and out of control in brain tumors and is, therefore, a hot topic for brain tumor diagnostic and therapeutic research. Alfa Cytology provides drug development services for brain tumors targeting EGFR. We are also developing EGFR-targeting nanotechnology approaches for drug delivery, as well as antibodies targeting extracellular EGFR and potential anti-EGFR antibody-drug conjugates, to provide new avenues for brain tumor treatment.M

Alfa Cytology focuses on anti-angiogenic therapies, and we provide targeted brain tumor drug development services targeting angiogenesis, particularly VEGF, to inhibit the proliferation of brain tumors, including GBM, by inhibiting the formation of new tumors blood vessels using angiogenesis inhibitors and drugs. Taking the VEGF target as an example, we have a full range of human anti-VEGF antibodies and can provide humanized monoclonal antibodies and anti-VEGF/VEGFR fusion protein development services against VEGF.

Drugs that exert anti-brain tumor effects by modulating epigenetic genes are becoming a hot topic of research. Alfa Cytology provides epigenetically targeted drug development services for clients in the field of brain tumor research. Given many potential targets, we have developed a systematic approach to discover and validate potential drug targets to focus on helping our clients in brain tumor drug development and improving drug efficacy.

Alfa Cytology offers brain tumor drug development services targeting siRNAs using multiple development strategies and providing clients with diverse development targets. In addition, we are also trying to chemically modify siRNAs to improve their resistance to nuclease degradation and enhance the stability of siRNAs without affecting their efficacy. We can encapsulate siRNA in nano-delivery bodies such as liposomes, inorganic nanocarriers, or polymeric materials such as dendrimers and polymeric micelles to improve siRNA stability.